Antisense Therapy for Infectious Diseases

Infectious diseases, particularly Tuberculosis (TB) caused by Mycobacterium tuberculosis, pose a significant global health challenge, with 1.6 million reported deaths in 2021, making it the most fatal disease caused by a single infectious agent. The rise of drug-resistant infectious diseases adds to the urgency of finding effective and safe intervention therapies. Antisense therapy uses antisense oligonucleotides (ASOs) that are short, chemically modified, single-stranded deoxyribonucleotide molecules complementary to their mRNA target. Due to their designed target specificity and inhibition of a disease-causing gene at the mRNA level, antisense therapy has gained interest as a potential therapeutic approach. This type of therapy is currently utilized in numerous diseases, such as cancer and genetic disorders. Currently, there are limited but steadily increasing studies available that report on the use of ASOs as treatment for infectious diseases. This review explores the sustainability of FDA-approved and preclinically tested ASOs as a treatment for infectious diseases and the adaptability of ASOs for chemical modifications resulting in reduced side effects with improved drug delivery; thus, highlighting the potential therapeutic uses of ASOs for treating infectious diseases.

[1]  Yeonjoon Kim.  Drug Discovery Perspectives of Antisense Oligonucleotides , 2023, Biomolecules & therapeutics.

[2]  A. Chinnaiyan,et al.  Antisense oligonucleotides to therapeutically target SARS-CoV-2 infection , 2023, PloS one.

[3]  M. Imamura,et al.  Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy. , 2022, Journal of hepatology.

[4]  W. Tarn,et al.  Antisense Oligonucleotide-Based Therapy of Viral Infections , 2021, Pharmaceutics.

[5]  E. Mercuri,et al.  Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1/2 Trial , 2021, Nucleic acid therapeutics.

[6]  S. P. Parihar,et al.  Targeting Molecular Inflammatory Pathways in Granuloma as Host-Directed Therapies for Tuberculosis , 2021, Frontiers in Immunology.

[7]  P. Shieh,et al.  Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: A randomized, double‐blind, placebo‐controlled, dose‐titration trial , 2021, Muscle & nerve.

[8]  J. Mendell,et al.  Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial , 2021, Journal of neuromuscular diseases.

[9]  Annemieke Aartsma-Rus,et al.  Delivery of oligonucleotide‐based therapeutics: challenges and opportunities , 2021, EMBO molecular medicine.

[10]  M. Gagliardi,et al.  The Challenges and Strategies of Antisense Oligonucleotide Drug Delivery , 2021, Biomedicines.

[11]  S. Crooke,et al.  Antisense technology: an overview and prospectus , 2021, Nature Reviews Drug Discovery.

[12]  R. Pettigrew,et al.  The Limitless Future of RNA Therapeutics , 2021, Frontiers in Bioengineering and Biotechnology.

[13]  Laura Michelle Streicher.  Exploring the future of infectious disease treatment in a post-antibiotic era: A comparative review of alternative therapeutics. , 2021, Journal of global antimicrobial resistance.

[14]  K. Jamialahmadi,et al.  Antisense Oligonucleotide (AS‐ODN) Technology: Principle, Mechanism and Challenges , 2020, Biotechnology and applied biochemistry.

[15]  R. Langer,et al.  Advances in oligonucleotide drug delivery , 2020, Nature Reviews Drug Discovery.

[16]  Shuaijian Ni,et al.  Recent Progress in Aptamer Discoveries and Modifications for Therapeutic Applications. , 2020, ACS applied materials & interfaces.

[17]  Harukazu Suzuki,et al.  Host-directed targeting of lincRNA-MIR99AHG suppresses intracellular growth of Mycobacterium tuberculosis , 2020, Nucleic acid therapeutics.

[18]  A. Vikram,et al.  Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development , 2020, Journal of clinical medicine.

[19]  Robert J. Lee,et al.  Cell-Penetrating Peptides in Diagnosis and Treatment of Human Diseases: From Preclinical Research to Clinical Application , 2020, Frontiers in Pharmacology.

[20]  S. Crooke,et al.  Phosphorothioate modified oligonucleotide–protein interactions , 2020, Nucleic acids research.

[21]  K. Shi,et al.  Structural basis of receptor recognition by SARS-CoV-2 , 2020, Nature.

[22]  C. Foged,et al.  Opportunities and Challenges in the Delivery of mRNA-Based Vaccines , 2020, Pharmaceutics.

[23]  P. Barthélémy,et al.  Lipid oligonucleotides as a new strategy for tackling the antibiotic resistance , 2020, Scientific Reports.

[24]  Li-Min Huang,et al.  The Host Heat Shock Protein MRJ/DNAJB6 Modulates Virus Infection , 2019, Front. Microbiol..

[25]  J. Kawai,et al.  Evaluation of off‐target effects of gapmer antisense oligonucleotides using human cells , 2019, Genes to cells : devoted to molecular & cellular mechanisms.

[26]  Jinkuk Kim,et al.  Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease. , 2019, The New England journal of medicine.

[27]  D. Stetsenko,et al.  A New Antisense Phosphoryl Guanidine Oligo-2′-O-Methylribonucleotide Penetrates Into Intracellular Mycobacteria and Suppresses Target Gene Expression , 2019, Front. Pharmacol..

[28]  J. Rossi,et al.  Dual Mechanisms of Action of Self-Delivering, Anti-HIV-1 FANA Oligonucleotides as a Potential New Approach to HIV Therapy , 2019, Molecular therapy. Nucleic acids.

[29]  Christopher E. Hart,et al.  Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index , 2019, Nature Biotechnology.

[30]  Christopher E. Hart,et al.  Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index , 2019, Nature Biotechnology.

[31]  S. Pulst,et al.  Antisense oligonucleotides , 2019, Neurology: Genetics.

[32]  P. Yenchitsomanus,et al.  Inhibition of dengue virus replication in monocyte-derived dendritic cells by vivo-morpholino oligomers. , 2019, Virus research.

[33]  S. Altman,et al.  Mesyl phosphoramidate antisense oligonucleotides as an alternative to phosphorothioates with improved biochemical and biological properties , 2019, Proceedings of the National Academy of Sciences.

[34]  Luan-Yin Chang,et al.  Interference of DNAJB6/MRJ Isoform Switch by Morpholino Inhibits Replication of HIV-1 and RSV , 2018, Molecular therapy. Nucleic acids.

[35]  S. Kauppinen,et al.  Development of Locked Nucleic Acid Antisense Oligonucleotides Targeting Ebola Viral Proteins and Host Factor Niemann-Pick C1. , 2018, Nucleic acid therapeutics.

[36]  A. Goyenvalle,et al.  Exon-skipping advances for Duchenne muscular dystrophy. , 2018, Human molecular genetics.

[37]  S. Dowdy,et al.  GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics. , 2018, Nucleic acid therapeutics.

[38]  Yanjin Zhang,et al.  Antisense Phosphorodiamidate Morpholino Oligomers as Novel Antiviral Compounds , 2018, Front. Microbiol..

[39]  J. Young,et al.  Liver-Targeted Anti-HBV Single-Stranded Oligonucleotides with Locked Nucleic Acid Potently Reduce HBV Gene Expression In Vivo , 2018, Molecular therapy. Nucleic acids.

[40]  J. Hegarty,et al.  Advances in therapeutic bacterial antisense biotechnology , 2017, Applied Microbiology and Biotechnology.

[41]  T. Tagami,et al.  Recent Trends in Clinical Trials Related to Carrier-Based Drugs. , 2017, Journal of pharmaceutical sciences.

[42]  H. Bui,et al.  Antisense oligonucleotides targeting translation inhibitory elements in 5′ UTRs can selectively increase protein levels , 2017, Nucleic acids research.

[43]  S. Dowdy.  Overcoming cellular barriers for RNA therapeutics , 2017, Nature Biotechnology.

[44]  J. Goldberg,et al.  Inhibition of Pseudomonas aeruginosa by Peptide-Conjugated Phosphorodiamidate Morpholino Oligomers , 2017, Antimicrobial Agents and Chemotherapy.

[45]  B. Baker,et al.  Pharmacology of Antisense Drugs. , 2017, Annual review of pharmacology and toxicology.

[46]  Jessica Chery.  RNA therapeutics: RNAi and antisense mechanisms and clinical applications. , 2016, Postdoc journal : a journal of postdoctoral research and postdoctoral affairs.

[47]  E. McNally,et al.  Welcome to the splice age: antisense oligonucleotide-mediated exon skipping gains wider applicability. , 2016, The Journal of clinical investigation.

[48]  Abolfazl Akbarzadeh,et al.  Application of liposomes in medicine and drug delivery , 2016, Artificial cells, nanomedicine, and biotechnology.

[49]  L. Good,et al.  Oxacillin sensitization of methicillin-resistant Staphylococcus aureus and methicillin-resistant Staphylococcus pseudintermedius by antisense peptide nucleic acids in vitro , 2015, BMC Microbiology.

[50]  S. Crooke,et al.  The rates of the major steps in the molecular mechanism of RNase H1-dependent antisense oligonucleotide induced degradation of RNA , 2015, Nucleic acids research.

[51]  Reto Guler,et al.  Host-directed drug therapy for tuberculosis. , 2015, Nature chemical biology.

[52]  M. Wood,et al.  An overview of the clinical application of antisense oligonucleotides for RNA-targeting therapies. , 2015, Current opinion in pharmacology.

[53]  Choukri Ben Mamoun,et al.  Targeting protein translation, RNA splicing, and degradation by morpholino-based conjugates in Plasmodium falciparum , 2015, Proceedings of the National Academy of Sciences.

[54]  K. Kataoka,et al.  DNA/RNA heteroduplex oligonucleotide for highly efficient gene silencing , 2015, Nature Communications.

[55]  Fritz Eckstein,et al.  Phosphorothioates, essential components of therapeutic oligonucleotides. , 2014, Nucleic acid therapeutics.

[56]  X. Xue,et al.  Antisense Growth Inhibition of Methicillin-Resistant Staphylococcus aureus by Locked Nucleic Acid Conjugated with Cell-Penetrating Peptide as a Novel FtsZ Inhibitor , 2014, Antimicrobial Agents and Chemotherapy.

[57]  L. van Doorn,et al.  In Vitro Antiviral Activity and Preclinical and Clinical Resistance Profile of Miravirsen, a Novel Anti-Hepatitis C Virus Therapeutic Targeting the Human Factor miR-122 , 2014, Antimicrobial Agents and Chemotherapy.

[58]  S. Crooke,et al.  Antisense Oligonucleotides Capable of Promoting Specific Target mRNA Reduction via Competing RNase H1-Dependent and Independent Mechanisms , 2014, PloS one.

[59]  W. Witola,et al.  Silencing of GRA10 protein expression inhibits Toxoplasma gondii intracellular growth and development. , 2014, Parasitology international.

[60]  Shuling Guo,et al.  Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice , 2014, Nucleic acids research.

[61]  K. Mikoshiba,et al.  Antisense Oligonucleotides Targeting Parasite Inositol 1,4,5-Trisphosphate Receptor Inhibits Mammalian Host Cell Invasion by Trypanosoma cruzi , 2014, Scientific Reports.

[62]  Ü. Langel,et al.  Cell-penetrating peptides: design, synthesis, and applications. , 2014, ACS nano.

[63]  Jing Yang,et al.  Pretreatment of Mice with Oligonucleotide prop5 Protects Them from Influenza Virus Infections , 2014, Viruses.

[64]  David E Greenberg,et al.  Gene-silencing antisense oligomers inhibit acinetobacter growth in vitro and in vivo. , 2013, The Journal of infectious diseases.

[65]  Sidney Altman,et al.  A peptide-morpholino oligomer conjugate targeting Staphylococcus aureus gyrA mRNA improves healing in an infected mouse cutaneous wound model. , 2013, International journal of pharmaceutics.

[66]  M. Seleem,et al.  Targeting listeria monocytogenes rpoA and rpoD genes using peptide nucleic acids. , 2013, Nucleic acid therapeutics.

[67]  T. Gilberger,et al.  PfSec13 is an unusual chromatin-associated nucleoporin of Plasmodium falciparum that is essential for parasite proliferation in human erythrocytes , 2013, Journal of Cell Science.

[68]  J. Setubal,et al.  Peptide nucleic acids inhibit growth of Brucella suis in pure culture and in infected murine macrophages. , 2013, International journal of antimicrobial agents.

[69]  D. Corey,et al.  Silencing disease genes in the laboratory and the clinic , 2012, The Journal of pathology.

[70]  G. Pauli,et al.  Human Cytomegalovirus (HCMV) – Revised , 2010, Transfusion Medicine and Hemotherapy.

[71]  S. Oh,et al.  A highly effective and long-lasting inhibition of miRNAs with PNA-based antisense oligonucleotides , 2009, Molecules and cells.

[72]  R. Crouch,et al.  Ribonuclease H: the enzymes in eukaryotes , 2009, The FEBS journal.

[73]  H. Feldmann,et al.  The Ebola virus ribonucleoprotein complex: a novel VP30-L interaction identified. , 2009, Virus research.

[74]  G. Ruthel,et al.  Chemical Modifications of Antisense Morpholino Oligomers Enhance Their Efficacy against Ebola Virus Infection , 2009, Antimicrobial Agents and Chemotherapy.

[75]  S. P. Walton,et al.  Impact of target mRNA structure on siRNA silencing efficiency: A large‐scale study , 2008, Biotechnology and bioengineering.

[76]  D. A. Stein,et al.  Inhibition of respiratory syncytial virus infections with morpholino oligomers in cell cultures and in mice. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[77]  A. Judge,et al.  Overcoming the innate immune response to small interfering RNA. , 2008, Human gene therapy.

[78]  K. Spurgers,et al.  Oligonucleotide antiviral therapeutics: Antisense and RNA interference for highly pathogenic RNA viruses , 2008, Antiviral Research.

[79]  M. Gait,et al.  miR-122 targeting with LNA/2'-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA-peptide conjugates. , 2007, RNA.

[80]  Brenda F Baker,et al.  Enhancement of SMN2 Exon 7 Inclusion by Antisense Oligonucleotides Targeting the Exon , 2007, PLoS biology.

[81]  Shunqing Xu,et al.  Inositol-1-phosphate synthetase mRNA as a new target for antisense inhibition of Mycobacterium tuberculosis. , 2007, Journal of biotechnology.

[82]  D. A. Stein,et al.  Inhibition of Multiple Subtypes of Influenza A Virus in Cell Cultures with Morpholino Oligomers , 2006, Antimicrobial Agents and Chemotherapy.

[83]  Shuhui Lim,et al.  ANTISENSE OLIGONUCLEOTIDES: FROM DESIGN TO THERAPEUTIC APPLICATION , 2006, Clinical and experimental pharmacology & physiology.

[84]  X. Bo,et al.  Antisense oligonucleotides targeted against asialoglycoprotein receptor 1 block human hepatitis B virus replication , 2006, Journal of viral hepatitis.

[85]  D. A. Stein,et al.  Inhibition of dengue virus translation and RNA synthesis by a morpholino oligomer targeted to the top of the terminal 3' stem-loop structure. , 2006, Virology.

[86]  Yin Chen,et al.  Peptide Nucleic Acid Antisense Oligomer as a Therapeutic Strategy against Bacterial Infection: Proof of Principle Using Mouse Intraperitoneal Infection , 2005, Antimicrobial Agents and Chemotherapy.

[87]  E. Harris,et al.  Enhancement of dengue virus translation: role of the 3' untranslated region and the terminal 3' stem-loop domain. , 2004, Virology.

[88]  S. Crooke,et al.  Determination of the Role of the Human RNase H1 in the Pharmacology of DNA-like Antisense Drugs* , 2004, Journal of Biological Chemistry.

[89]  L. Hubbard,et al.  A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS , 2002 .

[90]  G J van den Horn,et al.  Fomivirsen: a phosphorothioate oligunucleotide for the treatment of CMV retinitis , 1999 .

[91]  R. Padmanabhan,et al.  A Novel in Vitro Replication System for Dengue Virus , 1999, The Journal of Biological Chemistry.

[92]  S. Mande,et al.  Identification of the INO1 gene of Mycobacterium tuberculosis H37Rv reveals a novel class of inositol-1-phosphate synthase enzyme. , 1999, Journal of molecular biology.

[93]  B. Roehr.  Fomivirsen approved for CMV retinitis. , 1998, Journal of the International Association of Physicians in AIDS Care.

[94]  S. Agrawal,et al.  Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[95]  Z. Dominski,et al.  RNase H cleavage of RNA hybridized to oligonucleotides containing methylphosphonate, phosphorothioate and phosphodiester bonds , 1989 .

[96]  A. Lamond,et al.  Highly efficient chemical synthesis of 2'-O-methyloligoribonucleotides and tetrabiotinylated derivatives; novel probes that are resistant to degradation by RNA or DNA specific nucleases. , 1989, Nucleic acids research.

[97]  K. Jayaraman,et al.  Selective inhibition of Escherichia coli protein synthesis and growth by nonionic oligonucleotides complementary to the 3' end of 16S rRNA. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[98]  R. New,et al.  Antileishmanial activity of antimonials entrapped in liposomes , 1978, Nature.

[99]  V. Arechavala-Gomeza,et al.  Antisense RNA Therapeutics: A Brief Overview. , 2022, Methods in molecular biology.

[100]  D. Klinman,et al.  CpG Oligonucleotides as Vaccine Adjuvants. , 2021, Methods in molecular biology.

[101]  T. Yokota,et al.  DNA-RNA Heteroduplex Oligonucleotide for Highly Efficient Gene Silencing. , 2020, Methods in molecular biology.

[102]  K. E. Lundin,et al.  Chemical Development of Therapeutic Oligonucleotides. , 2019, Methods in molecular biology.

[103]  Diou Luo,et al.  Pre-mRNA Splicing Modulation by Antisense Oligonucleotides. , 2018, Methods in molecular biology.

[104]  R. Persson,et al.  Locked nucleic acid: modality, diversity, and drug discovery. , 2018, Drug discovery today.

[105]  Y. Kong,et al.  Antimicrobial activity of antisense peptide–peptide nucleic acid conjugates against non-typeable Haemophilus influenzae in planktonic and biofilm forms , 2017, The Journal of antimicrobial chemotherapy.

[106]  Shumei Liang,et al.  Inhibiting the growth of methicillin-resistant Staphylococcus aureus in vitro with antisense peptide nucleic acid conjugates targeting the ftsZ gene. , 2015, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[107]  Y. Hua,et al.  Antisense-mediated exon inclusion. , 2012, Methods in molecular biology.

[108]  Richard S Geary,et al.  Fomivirsen: clinical pharmacology and potential drug interactions. , 2002, Clinical pharmacokinetics.

[109]  M. Cornish,et al.  A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS. , 2002, American journal of ophthalmology.

[110]  M. Stephenson,et al.  Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. , 1978, Proceedings of the National Academy of Sciences of the United States of America.